Clinical Trials
2751
397 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1934
Terminated
4
0.1%
Recruiting
1049
38.1%
Suspended
1
0.0%
Withdrawn
3
0.1%
Active, not recruiting
7
0.3%
Unknown
77
2.8%
Completed
1220
44.4%
Not yet recruiting
390
14.2%
No approval data available
- An Iranian knowledge-based company has unveiled Spartina, a domestically produced tirzepatide medication for treating type 2 diabetes, obesity, and sleep apnea. - The drug features a dual mechanism targeting both GIP and GLP-1 receptors, demonstrating effectiveness rates of 25-30% for weight loss compared to less than 10% for previous obesity medications. - Spartina reduces three-month average blood sugar by 2.5 percent and has received approval for obesity and sleep apnea treatment with minimal prescription restrictions. - This launch represents Iran's pharmaceutical self-sufficiency strategy, with the country now fulfilling approximately 97% of its pharmaceutical needs through domestic production capabilities.
- A network meta-analysis reveals that pregabalin and topiramate, with or without vitamin D3, significantly reduce migraine frequency in children and adolescents. - The study highlights that pregabalin resulted in a 63% reduction in migraine frequency, which increased to 88% when combined with vitamin D supplementation. - Flunarizine, levetiracetam, riboflavin, cinnarizine, and amitriptyline also showed potential in reducing migraine frequency, though further studies are needed for confirmation. - Amitriptyline, topiramate and valproate were associated with the greatest adverse events compared to placebo, underscoring the need for careful monitoring.
